LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Statement – Vaccine production scale up: International collaboration remains the key

25/03/2021
PRESS RELEASE

EuropaBio Statement – Vaccine production scale up: International collaboration remains the key

Increasing the manufacturing capacity for vaccines in Europe at such unprecedented scale and in such short timeframes, is a very complex and challenging undertaking. It requires the support of all possible resources in the value chain in Europe and beyond. With the Covid-19 crisis, recent supply tensions in medicines and critical equipment have shown that mobility restrictions due to closure of borders, or exports bans are not the solution to prevent shortages or to ensure continuity of supply for biotechnology-based products.

It is the diversification of manufacturing sources that lowers the risk from local dependency. Many of our EuropaBio members have, over the years, built international manufacturing networks that ensure medicines supply worldwide. It is these diversified and inter-dependant global supply chains that have assured continuity of supply of innovative treatments when the Covid-19 crisis emerged in Europe in the spring of 2020.

In order to avoid future issues for vaccines production, it is critical to build strong and resilient supply chains through international cooperation. The only viable solution is to work together for continued increase of production capacity, ramping up existing facilities and establishing new international production partnerships to create the reliable supply chains needed. This ambition has been recently accelerated through Commissioner Breton’s initiative on vaccine production capacities. It is vital that these joint efforts from EU institutions, governments, regulators and the biotechnology industry are not endangered by short term vaccine mobility restrictions that place national priorities above continuity of global vaccines supplies and production increase.

Download the full PRESS RELEASE below.

EuropaBio Statement – Vaccine production scale up: International collaboration remains the key


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.